You are here

Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain

Last updated on August 21, 2018

FOR MORE INFORMATION
Study Location
Meitoh Hospital
Nagoya, Aichi, 465-0025 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Low Back Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Duration of chronic low back pain for ≥3 months, and treatment with agents for low
back pain for ≥3 months.

- Primary location of low back pain must be between the 12th thoracic vertebra and the
lower gluteal folds, with or without radiation into the posterior thigh, classified as
Category 1 or 2 according to the classification of the Quebec Task Force in Spinal
Disorders.

- Subjects must be experiencing some benefits from their current stable dose regimen of
oral NSAID (celecoxib, loxoprofen or meloxicam) treatment as described in the
protocol, be tolerating their NSAID regimen, be taking this medication regularly
during the 30 day period prior to the Screening visit and must have had some
improvement in low back pain, but still require additional pain relief at Screening.

- Subjects must maintain a stabilized, protocol specified NSAID dose regimen for at
least the final 2 or 3 weeks of the Screening period.

- Low Back Pain Intensity (LBPI) score of ≥5 at Screening.

- Subjects must be willing to discontinue all pain medications for chronic low back pain
except rescue medication and investigational product and not use prohibited pain
medications throughout the duration of the study.

- Female subjects of childbearing potential and at risk for pregnancy must agree to
comply with protocol specified contraceptive requirements.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects exceeding protocol defined BMI limits.

- Diagnosis of osteoarthritis of the knee or hip as defined by the ACR combined clinical
and radiographic criteria.

- Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or
Grade > or =3 radiographic evidence of knee osteoarthritis will be excluded.

- Subjects who have Kellgren Lawrence Grade osteoarthritis but who do not meet ACR criteria and do not have pain associated
with their knee osteoarthritis will be allowed.

- Subjects with symptoms and radiologic findings consistent with osteoarthritis in the
shoulder.

- History of lumbosacral radiculopathy within the past 2 years, history of spinal
stenosis associated with neurological impairment, or history of neurogenic
claudication.

- Back pain due to recent major trauma within 6 months prior to Screening.

- Surgical intervention during the past 6 months for the treatment of low back pain.

- Planned surgical procedure during the duration of the study.

- History or radiographic evidence of other diseases that could confound efficacy or
safety assessments (eg, rheumatoid arthritis).

- History or radiographic evidence of orthopedic conditions that may increase the risk
of, or confound assessment of joint safety conditions during the study.

- History of osteonecrosis or osteoporotic fracture.

- History of significant trauma or surgery to a knee, hip, or shoulder within the
previous year.

- Signs or symptoms of carpal tunnel syndrome in the one year prior to Screening.

- Considered unfit for surgery based upon American Society of Anesthesiologists physical
classification system for surgery grading, or subjects who would not be willing to
undergo joint replacement surgery if required.

- History of intolerance or hypersensitivity to celecoxib/acetaminophen or any of its
excipients or existence of a medical condition or use of concomitant medication for
which the use of celecoxib/acetaminophen is contraindicated.

- Use of prohibited medications or prohibited non-pharmacological treatments without the
appropriate washout period (if applicable) prior to Screening or IPAP.

- History of known alcohol, analgesic or narcotic abuse within 2 years of Screening.

- Presence of drugs of abuse or illegal drugs in the urine toxicology screen obtained at
Screening.

- History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal
antibody or IgG-fusion protein.

- Signs and symptoms of clinically significant cardiac disease.

- Poorly controlled hypertension as defined in the protocol or taking an
antihypertensive that has not been stable for at least 1 month prior to Screening.

- Evidence of protocol defined orthostatic hypotension at Screening.

- Disqualifying score on the Survey of Autonomic Symptoms questionnaire at Screening.

- Diagnosis of a transient ischemic attack in the 6 months prior to Screening, diagnosis
of stroke with residual deficits that would preclude completion of required study
activities.

- History of cancer within 5 years prior to Screening, except for cutaneous basal cell
or squamous cell cancer resolved by excision.

- Expected to undergo a therapeutic procedure or to use any analgesic other than those
specified in the protocol throughout the pre-treatment and treatment periods that is
likely to confound assessment of analgesic efficacy or safety.

- Previous exposure to exogenous NGF or to an anti-NGF antibody.

- Screening AST, ALT, serum creatinine or HbA1c values that exceed protocol defined
limits.

- Positive Hepatitis B, Hepatitis C, or HIV tests at screening indicative of current
infection.

- History, diagnosis, or signs and symptoms of clinically significant neurological
disease or clinically significant psychiatric disorder.

- Pregnant, breastfeeding or female subjects of childbearing potential who are unwilling
or unable to follow protocol required contraceptive requirements.

- Participation in other investigational drug studies within protocol defined time
limits.

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

NCT02725411
Pfizer
Active, not recruiting
Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pain
NCT01266161
All Genders
16+
Years
Multiple Sites
Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
NCT02433158
All Genders
6+
Years
Multiple Sites
Low Back Pain
NCT02528253
All Genders
18+
Years
Multiple Sites
Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Japanese Adult Subjects With Chronic Low Back Pain
This study will investigate the long-term safety and efficacy of a fixed dose of tanezumab 5 mg and 10 mg administered subcutaneously (SC) seven times at 8 week intervals. The primary objective of this study is to evaluate the long term safety of tanezumab 5 mg and 10 mg administrated SC every 8 weeks (7 administrations). In addition, the study will evaluate the long term analgesic efficacy of tanezumab 5 mg and 10 mg SC administered every 8 weeks (7 administrations).
This is a randomized, double-blind, active-controlled, multicenter, parallel-group Phase 3 study of the safety and efficacy of tanezumab when administered by SC injection for up to 56 weeks in subjects with chronic low back pain. Subjects will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio. Treatment groups will include: 1) Placebo SC matching tanezumab administered at an 8-week interval (total of 7 times) plus celecoxib 100 mg twice a day (BID) to be administered orally for 56 weeks; 2) Tanezumab 5 mg SC administered at an 8-week interval (total of 7 times) plus placebo matching celecoxib to be administered orally BID for 56 weeks; 3) Tanezumab 10 mg SC administered at an 8-week interval (total of 7 times) plus placebo matching celecoxib to be administered orally BID for 56 weeks. The study is designed with a total duration (post-randomization) of up to 80 weeks and will consist of three periods: Screening (up to 37 days; includes a Washout Period and an Initial Pain Assessment Period [IPAP]), a Double-blind Treatment Period (56 weeks) and a Follow-up Period (24 weeks). The Screening Period (beginning up to 37 days prior to Randomization) includes a Washout Period (lasting 2 to 32 days), if required, and an IPAP (the 5 days prior to Randomization/Baseline). Prior to entering the study, subjects must be experiencing some benefit (eg, analgesic effect) from their current stable dose regimen of oral NSAID (celecoxib, loxoprofen or meloxicam) treatment, be tolerating their NSAID regimen, be taking this medication regularly (defined as an average of at least 5 days per week) during the 30 day period prior to the Screening Visit.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Low Back Pain
  • Drug: Celecoxib
    Orally administered Celecoxib 100 mg twice daily for 56 weeks
  • Biological: Tanezumab 5 mg
    Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
  • Biological: Tanezumab 10 mg
    Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
  • Drug: Placebo for celecoxib
    Orally administered the placebo twice daily for 56 weeks
  • Biological: Placebo for tanezumab
    Subcutaneous injection of the placebo every 8 weeks for 56 weeks
  • Active Comparator: Celecoxib
    Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
    Interventions:
    • Drug: Celecoxib
    • Biological: Placebo for tanezumab
  • Experimental: Tanezumab 5 mg
    Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
    Interventions:
    • Biological: Tanezumab 5 mg
    • Drug: Placebo for celecoxib
  • Experimental: Tanezumab 10 mg
    Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
    Interventions:
    • Biological: Tanezumab 10 mg
    • Drug: Placebo for celecoxib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
June 13, 2019
June 13, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Duration of chronic low back pain for ?3 months, and treatment with agents for low back pain for ?3 months.
  • Primary location of low back pain must be between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh, classified as Category 1 or 2 according to the classification of the Quebec Task Force in Spinal Disorders.
  • Subjects must be experiencing some benefits from their current stable dose regimen of oral NSAID (celecoxib, loxoprofen or meloxicam) treatment as described in the protocol, be tolerating their NSAID regimen, be taking this medication regularly during the 30 day period prior to the Screening visit and must have had some improvement in low back pain, but still require additional pain relief at Screening.
  • Subjects must maintain a stabilized, protocol specified NSAID dose regimen for at least the final 2 or 3 weeks of the Screening period.
  • Low Back Pain Intensity (LBPI) score of ?5 at Screening.
  • Subjects must be willing to discontinue all pain medications for chronic low back pain except rescue medication and investigational product and not use prohibited pain medications throughout the duration of the study.
  • Female subjects of childbearing potential and at risk for pregnancy must agree to comply with protocol specified contraceptive requirements.

Exclusion Criteria:

  • Subjects exceeding protocol defined BMI limits.
  • Diagnosis of osteoarthritis of the knee or hip as defined by the ACR combined clinical and radiographic criteria.

    • Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or Grade > or =3 radiographic evidence of knee osteoarthritis will be excluded.
    • Subjects who have Kellgren Lawrence Grade < or =2 radiographic evidence of knee osteoarthritis but who do not meet ACR criteria and do not have pain associated with their knee osteoarthritis will be allowed.
  • Subjects with symptoms and radiologic findings consistent with osteoarthritis in the shoulder.
  • History of lumbosacral radiculopathy within the past 2 years, history of spinal stenosis associated with neurological impairment, or history of neurogenic claudication.
  • Back pain due to recent major trauma within 6 months prior to Screening.
  • Surgical intervention during the past 6 months for the treatment of low back pain.
  • Planned surgical procedure during the duration of the study.
  • History or radiographic evidence of other diseases that could confound efficacy or safety assessments (eg, rheumatoid arthritis).
  • History or radiographic evidence of orthopedic conditions that may increase the risk of, or confound assessment of joint safety conditions during the study.
  • History of osteonecrosis or osteoporotic fracture.
  • History of significant trauma or surgery to a knee, hip, or shoulder within the previous year.
  • Signs or symptoms of carpal tunnel syndrome in the one year prior to Screening.
  • Considered unfit for surgery based upon American Society of Anesthesiologists physical classification system for surgery grading, or subjects who would not be willing to undergo joint replacement surgery if required.
  • History of intolerance or hypersensitivity to celecoxib/acetaminophen or any of its excipients or existence of a medical condition or use of concomitant medication for which the use of celecoxib/acetaminophen is contraindicated.
  • Use of prohibited medications or prohibited non-pharmacological treatments without the appropriate washout period (if applicable) prior to Screening or IPAP.
  • History of known alcohol, analgesic or narcotic abuse within 2 years of Screening.
  • Presence of drugs of abuse or illegal drugs in the urine toxicology screen obtained at Screening.
  • History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
  • Signs and symptoms of clinically significant cardiac disease.
  • Poorly controlled hypertension as defined in the protocol or taking an antihypertensive that has not been stable for at least 1 month prior to Screening.
  • Evidence of protocol defined orthostatic hypotension at Screening.
  • Disqualifying score on the Survey of Autonomic Symptoms questionnaire at Screening.
  • Diagnosis of a transient ischemic attack in the 6 months prior to Screening, diagnosis of stroke with residual deficits that would preclude completion of required study activities.
  • History of cancer within 5 years prior to Screening, except for cutaneous basal cell or squamous cell cancer resolved by excision.
  • Expected to undergo a therapeutic procedure or to use any analgesic other than those specified in the protocol throughout the pre-treatment and treatment periods that is likely to confound assessment of analgesic efficacy or safety.
  • Previous exposure to exogenous NGF or to an anti-NGF antibody.
  • Screening AST, ALT, serum creatinine or HbA1c values that exceed protocol defined limits.
  • Positive Hepatitis B, Hepatitis C, or HIV tests at screening indicative of current infection.
  • History, diagnosis, or signs and symptoms of clinically significant neurological disease or clinically significant psychiatric disorder.
  • Pregnant, breastfeeding or female subjects of childbearing potential who are unwilling or unable to follow protocol required contraceptive requirements.
  • Participation in other investigational drug studies within protocol defined time limits.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Japan
 
 
NCT02725411
A4091063
JAPAN CLBP SC STUDY ( Other Identifier: Alias Study Number )
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now